Original Research
Published on 18 Aug 2025
Ruxolitinib and decitabine plus a busulfan–cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes
in Alloimmunity and Transplantation
- 253 views